Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: Retrospective-prospective cohort study from 2004 to 2007

Eurosurveillance

Volumn 18, Issue 40, 2013, Pages

  Anderson, L F ^a   Tamne, S ^a   Watson, J P ^b   Cohen, T ^c   Mitnick, C ^d   Brown, T ^a   Drobniewski, F ^a   Abubakar, I ^a,e  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; IMIPENEM; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHILD; COMORBIDITY; DISEASE TRANSMISSION; DRUG SENSITIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; NEWBORN; PATIENT CARE; PROSPECTIVE STUDY; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 84885217755     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2013.18.40.20601     Document Type: Article

References (52)

1. World Health Organization (WHO). Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: WHO; 2010. Available from:http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf
2. Anderson L, Moore J, Kruijshaar M, Pedrazzoli D, Bradshaw L, Crofts J, et al. Tuberculosis in the UK: report on tuberculosis surveillance in the UK 2010. London: Health Protection Agency; 2010. Available from:http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1287143594275
3. White VL, Moore-Gillon J. Resource implications of patients with multidrug resistant tuberculosis. Thorax. 2000;55(11):962-3. http://dx.doi.org/10.1136/thorax.55.11.962. PMid:11050268. PMCid:PMC1745633.
4. World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. Geneva: WHO; 2008. Available from:http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf
5. World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update. Geneva: WHO; 2011. Available from:http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf
6. Partners In Health (PIH). The PIH guide to the medical management of multidrug-resistant tuberculosis. Boston, MA: PIH; 2003. Available from: http://www.pih.org/library/pih-guide-to-the-medical-management-of-multidrug-resistant-tuberculosis
7. Department of Health (DOH). The Interdepartmental Working Group on Tuberculosis: The prevention and control of tuberculosis in the United Kingdom. London: DOD; 1998. Available from:http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4006196?IdcService=GET_FILE&dID=28094&Rendition=Web
8. National Institute for Health and Clinical Excellence (NICE). Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2011 update. http://www.nice.org.uk/nicemedia/live/13422/53642/53642.pdf
9. Pedrazzoli D, Anderson L, Lalor M, Davidson J, Abubakar I, Thomas L. Tuberculosis in the UK: annual report on tuberculosis surveillance in the UK, 2013. London. London: Public Health England; 2013. Available from:http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139689583?utm_source%3D1be16992-d8f0-4483-8eb5-3137299827e1%26utm_medium%3Drss%26utm_campaign%3Dlong
10. World Health Organization (WHO). Global tuberculosis report 2012. Geneva: WHO; 2012. Available from:http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf
11. Department of Health (DOH). Stopping tuberculosis in England: an action plan from the Chief Medical Officer. London: DOH; 2004. Available from:http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4100860.pdf
12. European Centre for Disease Prevention and Control (ECDC). Progressing towards TB elimination. A follow-up to the Framework Action Plan to Fight Tuberculosis in the European Union. Stockholm: ECDC; 2010. Available from:http://ecdc.europa.eu/en/publications/Publications/101111_SPR_Progressing_towards_TB_elimination.pdf
13. World Health Organization (WHO). International statistical classification of diseases and related health problems. 10th revision, edition 2010. Geneva: WHO; 2005. Available from:http://www.who.int/classifications/icd/ICD10Volume2_en_2010.pdf
14. Drobniewski FA, Caws M, Gibson A, Young D. Modern laboratory diagnosis of tuberculosis. Lancet Infect Dis. 2003;3(3):141-7. http://dx.doi.org/10.1016/S1473-3099(03)00544-9
15. Ditah IC, Reacher M, Palmer C, Watson JM, Innes J, Kruijshaar ME, et al. Monitoring tuberculosis treatment outcome: analysis of national surveillance data from a clinical perspective. Thorax. 2008;63(5):440-6. http://dx.doi.org/10.1136/thx.2006.073916. PMid:17615085.
16. European Centre for Disease Prevention and Control (ECDC)/ World Health Organization Regional Office for Europe. Tuberculosis surveillance in Europe 2008. Stockholm: ECDC; 2010. Available from:http://www.euro.who.int/__data/assets/pdf_file/0007/78856/E93600.pdf
17. Ferrara G, Richeldi L, Bugiani M, Cirillo D, Besozzi G, Nutini S, et al. Management of multidrug-resistant tuberculosis in Italy. Int J Tuberc Lung Dis. 2005;9(5):507-13. PMid:15875921.
18. Uffredi ML, Truffot-Pernot C, Dautzenberg B, Renard M, Jarlier V, Robert J. An intervention programme for the management of multidrug-resistant tuberculosis in France. Int J Antimicrob Agents. 2007;29(4):434-9. http://dx.doi.org/10.1016/j.ijantimicag.2006.11.023. PMid:17300920.
19. Eker B, Ortmann J, Migliori GB, Sotgiu G, Muetterlein R, Centis R, et al. Multidrug-and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis. 2008;14(11):1700-6. http://dx.doi.org/10.3201/eid1411.080729. PMid:18976552. PMCid:PMC2630755.
20. Pedrazzoli D, Fulton N, Anderson L, Lalor M, Abubakar I, Zenner D. Tuberculosis in the UK: 2012 report. London: Health Protection Agency; 2012. Available from:http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317134913404
21. World Health Organization (WHO). Anti-tuberculosis drug resistance in the world: fourth global report. Geneva: WHO; 2008. Available from: http://www.who.int/tb/publications/2008/drs_report4_26feb08.pdf
22. Crofts JP, Pebody R, Grant A, Watson JM, Abubakar I. Estimating tuberculosis case mortality in England and Wales, 2001-2002. Int J Tuberc Lung Dis. 2008;12(3):308-13. PMid:18284837.
23. Haar CH, Cobelens FG, Kalisvaart NA, van Gerven PJ, van der Have JJ. HIV-related mortality among tuberculosis patients in the Netherlands, 1993-2001. Int J Tuberc Lung Dis. 2007;11(9):1038-41. PMid:17918662.
24. Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis. 2010;14(4):413-9. PMid:20202298. PMCid:PMC3005763.
25. Horne DJ, Hubbard R, Narita M, Exarchos A, Park DR, Goss CH. Factors associated with mortality in patients with tuberculosis. BMC Infect Dis. 2010;10:258. http://dx.doi.org/10.1186/1471-2334-10-258. PMid:20799975. PMCid:PMC2936899.
26. Duarte EC, Bierrenbach AL, Barbosa da SJ Jr, Tauil PL, de Fátima Duarte E. Factors associated with deaths among pulmonary tuberculosis patients: a case-control study with secondary data. J Epidemiol Community Health. 2009;63(3):233-8. http://dx.doi.org/10.1136/jech.2008.078972. PMid:19066188.
27. Balabanova Y, Radiulyte B, Davidaviciene E, Hooper R, Ignatyeva O, Nikolayevskyy V, et al. Survival of drug resistant tuberculosis patients in Lithuania: retrospective national cohort study. BMJ Open. 2011;1(2):e000351. http://dx.doi.org/10.1136/bmjopen-2011-000351. PMid:22123922. PMCid:PMC3225583.
28. Oursler KK, Moore RD, Bishai WR, Harrington SM, Pope DS, Chaisson RE. Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis. 2002;34(6):752-9. http://dx.doi.org/10.1086/338784. PMid:11850859.
29. Rao VK, Iademarco EP, Fraser VJ, Kollef MH. The impact of comorbidity on mortality following in-hospital diagnosis of tuberculosis. Chest. 1998;114(5):1244-52. http://dx.doi.org/10.1378/chest.114.5.1244. PMid:9823996.
30. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg. 2009;80(4):634-9. PMid:19346391. PMCid:PMC2750857.
31. American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. MWR Recomm Rep. 2003;52(RR-11):1-77.
32. Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis. 1996;77(1):37-42. http://dx.doi.org/10.1016/S0962-8479(96)90073-8.
33. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4(9):e6914. http://dx.doi.org/10.1371/journal.pone.0006914. PMid:19742330. PMCid:PMC2735675.
34. Chiang CY, Enarson DA, Yu MC, Bai KJ, Huang RM, Hsu CJ, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J. 2006;28(5):980-5. http://dx.doi.org/10.1183/09031936.06.00125705. PMid:16837502.
35. David HL, Laszlo A, Rastogi N. Mode of action of antimycobacterial drugs. Acta Leprol. 1989;7 Suppl 1:189-94. PMid:2503988.
36. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2010;51(1):6-14. http://dx.doi.org/10.1086/653115. PMid:20504231.
37. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis, of 9,153 patients. PLoS Medicine. 2012;9(8):e1001300. http://dx.doi.org/10.1371/journal.pmed.1001300. PMid:22952439. PMCid:PMC3429397.
38. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs. 2007;67(14):2077-99. http://dx.doi.org/10.2165/00003495-200767140-00007. PMid:17883288.
39. Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev. 2008;(1):CD004795. PMid:18254061.
40. Lambregts-van Weezenbeek CS, Jansen HM, Nagelkerke NJ, van Klingeren B, Veen J. Nationwide surveillance of drug-resistant tuberculosis in the Netherlands: rates, risk factors and treatment outcome. Int J Tuberc Lung Dis. 1998;2(4):288-95. PMid:9559399.
41. Migliori GB, Lange C, Girardi E, Centis R, Besozzi G, Kliiman K, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Respir J. 2008;31(4):904-5. http://dx.doi.org/10.1183/09031936.00159807. PMid:18378786.
42. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi-and extensively drug-resistant pulmonary TB. Eur Respir J. 2009;33(5):1085-94. http://dx.doi.org/10.1183/09031936.00155708. PMid:19164345.
43. Tahaoǧlu K, Törün T, Sevim T, Ataç G, Kir A, Karasulu L, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med. 2001;345(3):170-4. http://dx.doi.org/10.1056/NEJM200107193450303. PMid:11463011.
44. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365(9456):318-26. PMid:15664227.
45. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest. 2000;117(3):744-51. http://dx.doi.org/10.1378/chest.117.3.744. PMid:10713001.
46. Migliori GB, Lange C, Centis R, Sotgiu G, Mutterlein R, Hoffmann H, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J. 2008;31(6):1155-9. http://dx.doi.org/10.1183/09031936.00028708. PMid:18515555.
47. Migliori GB, Sotgiu G, D'Arcy Richardson M, Centis R, Facchini A, Guenther G, et al. MDR-TB and XDR-TB: drug resistance and treatment outcomes. Eur Respir J. 2009;34(3):778-9. http://dx.doi.org/10.1183/09031936.00059409. PMid:19720816.
48. World Health Organization (WHO). Definitions and reporting framework for tuberculosis-2013 revision. Geneva: WHO; 2013. Available from: http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
49. Leahy AU, Lipman M, Hetzel M, Kon OM, Hopkins S, Abubakar I. Do we need bacteriological confirmation of cure in uncomplicated TB? Eur Respir J. 2013;42(3):860-3. http://dx.doi.org/10.1183/09031936.00190912. PMid:24000254.
50. Crofts JP, Andrews NJ, Barker RD, Delpech V, Abubakar I. Risk factors for recurrent tuberculosis in England and Wales, 1998-2005. Thorax. 2010; 65(4):310-4. http://dx.doi.org/10.1136/thx.2009.124677. PMid:20388755.
51. British Thoracic Society (BTS). British Thoracic Society Tuberculosis Specialist Advisory Group. London: BTS; 2011. [Accessed 13 Sep 2013]; Available from: http://www.brit-thoracic.org.uk/delivery-of-respiratory-care/tuberculosis/bts-tb-specialist-advisory-group.aspx
52. Combellick J, Zuroweste E, Gany FM. TBNet: the impact of an innovative public-private intervention on tuberculosis control among an internationally mobile population. J Immigr Refug Stud. 2011;9(3): 229-241. http://dx.doi.org/10.1080/15562948.2011.592805